Revolutionizing Single-Cell Multiomics: BioSkryb and Tecan’s Breakthrough Workflow

The biotechnology sector is on the cusp of a paradigm shift, thanks to BioSkryb Genomics and Tecan Group’s recently unveiled single-cell multiomics workflow. This collaboration merges BioSkryb’s ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit with Tecan’s Uno Single Cell Dispenser™, creating a high-throughput solution that promises to redefine genomic and transcriptomic research. By streamlining workflows and democratizing access to multiomics data, the partnership addresses a critical bottleneck in the field: the time-consuming and costly reliance on fluorescence-activated cell sorting (FACS).

Ask Aime: Will BioSkryb Genomics' collaboration with Tecan Group revolutionize biotech research?

The Technology: Precision Meets Scalability
The workflow’s core advantage lies in its ability to generate sequencing-ready libraries in under ten hours—a stark improvement over traditional methods that often require days of manual handling. The Uno dispenser’s picoliter-level precision ensures minimal sample loss, while BioSkryb’s ResolveOME chemistry enables simultaneous whole-genome and transcriptome analysis. This dual capability is a game-changer for researchers studying complex diseases like cancer, where understanding genomic mutations alongside gene expression is essential.

Market Potential: A $10 Billion Opportunity
The global single-cell sequencing market is projected to reach $10.2 billion by 2030, growing at a CAGR of 18.6% driven by advancements in precision medicine and oncology research. BioSkryb and Tecan’s solution directly targets this demand, offering a streamlined path to high-resolution data. Labs, particularly those without access to advanced FACS infrastructure, stand to benefit most. Suresh Pisharody, BioSkryb’s CEO, emphasizes that the workflow brings “next-generation single-cell multiomics within reach of every lab,” a claim bolstered by the system’s compatibility with standard lab workflows and reduced hands-on time.

Competitive Landscape: Automation as the Edge
While competitors like 10x Genomics and Illumina dominate the single-cell sequencing space, BioSkryb and Tecan’s automation-first approach sets them apart. shows steady growth, reflecting investor confidence in its automation tools. The integration of the Uno dispenser’s precision with BioSkryb’s chemistry could carve out a niche in markets underserved by existing platforms, such as academic labs and smaller biotechs.

Financial Implications: A Win for Both Sectors
BioSkryb, a privately held firm, gains a scalable commercial partner in Tecan, which has a proven track record in lab automation. For Tecan, this collaboration expands its footprint in the rapidly growing multiomics sector. The partnership’s emphasis on reproducibility and scalability aligns with the industry’s push for “data-first” drug discovery, a trend driving mergers and acquisitions in the biotech space.

Conclusion: A Catalyst for Precision Medicine
BioSkryb and Tecan’s workflow is not merely an incremental improvement—it’s a foundational shift. By reducing experiment time, lowering costs, and enabling thousands of cells to be analyzed in parallel, the technology accelerates biological discovery at a critical juncture for precision medicine. With cancer research alone expected to drive 22% of global single-cell sequencing spending by 2030, the demand for such tools is insatiable.

The collaboration’s success hinges on Tecan’s automation expertise and BioSkryb’s molecular know-how, a synergy that could lead to long-term partnerships in drug development. For investors, the duo represents a compelling play on the convergence of automation and genomic innovation—a sector poised to redefine healthcare’s future.

In a market where time and scalability are currency, BioSkryb and Tecan have struck gold.